One Colombian's Quest For A Malaria Vaccine

In March of this year, Colombia heard some important news that had nothing to do with the country’s infamous drug trade. A Colombian scientist named Manuel E. Patarroyo published a study in Nature showing that an experimental vaccine he had developed was tantalizingly effective against malaria, a disease that threatens two-thirds of the world’s population. Until then, the parasite that causes malaria had stubbornly resisted the efforts of hundreds of researchers in the U.S. and Eur

| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

In March of this year, Colombia heard some important news that had nothing to do with the country’s infamous drug trade. A Colombian scientist named Manuel E. Patarroyo published a study in Nature showing that an experimental vaccine he had developed was tantalizingly effective against malaria, a disease that threatens two-thirds of the world’s population.

Until then, the parasite that causes malaria had stubbornly resisted the efforts of hundreds of researchers in the U.S. and Europe to develop a vaccine. So how was a relatively obscure scientist from the Third World—one who has been forced to cope with poor funding, inadequate facilities, even terrorists—able to achieve the first promising results?

The answer is that innovation and creativity aren’t found only in well-funded, prestigious laboratories in the developed world. Patarroyo’s approach to creating a vaccine, for example, was particularly novel. He devised a mixture of three different synthetic peptides, each a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • John Lauerman

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo